The American Heart Association (AHA) has issued a scientific statement recommending that major depre...
In July, lurasidone—a dopamine receptor 2 (D2) blocker originally approved to treat schizophrenia—wa...
The U.S. Food and Drug Administration (FDA) has approved new indications for the atypical antipsycho...
